Biome Australia Ltd (BIO) AI Stock Analysis

• Market Cap: AU$100.17M
• Dividend Yield: N/A
• Average Volume (3M): 278.69K
• Price to Earnings (P/E): 465.0
• Beta (1Y): 1.62
• Revenue Growth: 41.57%
• EPS Growth: N/A
• Country: US
• Employees: 30
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 222,609,240
• 10 Day Avg. Volume: 235,222
• 30 Day Avg. Volume: 278,692
• PEG Ratio: -4.12
• Price to Book (P/B): 21.27
• Price to Sales (P/S): 5.40
• P/FCF Ratio: -34.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.00
• Price Target Upside: 150.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: AU$0.49 ▲(23.00% Upside)

The score is driven primarily by decent financial progress (revenue growth and strong gross margin) and improving technical momentum. However, the overall rating is held back by cash flow weakness (negative operating cash flow) and a very stretched valuation (P/E 455).

Positive Factors

Revenue Growth

Sustained top-line growth of ~16% indicates expanding commercial traction or successful licensing activity, which over the next 2-6 months supports scale economics, funds continued R&D and clinical programs, and reduces the execution risk associated with stagnant revenues.

Gross Margin Strength

A high gross margin (~61%) reflects strong product economics or efficient cost of goods sold, giving the company durability to invest in pipeline development. Over the medium term this margin buffer improves the odds of reaching sustainable profitability as revenues scale.

Manageable Leverage

Moderate leverage with a strong equity ratio and positive ROE provides financial flexibility to fund clinical programs and partnerships without excessive distress. This capital structure reduces refinancing risk and supports multi-quarter operational plans.

Negative Factors

Negative Operating Cash Flow

Negative operating cash flow indicates weak cash conversion from core activities, forcing reliance on financing, partnership payments or asset sales. Over several months this constrains funding for trials and commercialization, increasing execution and refinancing risk.

Thin Net Profitability

Very low net margin (~1.2%) leaves little buffer against cost inflation, trial delays or pricing pressure. Structurally, thin profitability implies earnings are vulnerable and the company may struggle to self-fund growth without improving margins or securing external capital.

Lumpy Licensing-Dependent Revenue

Dependence on upfront and milestone licensing payments creates lumpy, timing-dependent revenues and makes cash flow forecasting difficult. Structurally this increases volatility in available funding for R&D and operations and can complicate multi-quarter planning.

Biome Australia Ltd Business Overview & Revenue Model

Company Description

Biome Australia Ltd (BIO) is an innovative biotechnology company focused on developing and commercializing advanced biopharmaceuticals and therapeutics. Operating primarily in the life sciences sector, BIO is dedicated to addressing unmet medical needs through its cutting-edge research in areas such as oncology, neurology, and infectious diseases. The company leverages proprietary technology platforms to create novel drug candidates, aiming to improve patient outcomes.

How the Company Makes Money

Biome Australia Ltd generates revenue primarily through the development and commercialization of its biopharmaceutical products. The company’s revenue model includes income from product sales, licensing agreements, and partnerships with larger pharmaceutical firms that facilitate the clinical development and distribution of its products. Key revenue streams consist of upfront payments from licensing deals, milestone payments tied to the successful achievement of development stages, and royalties on future sales of partnered products. Additionally, significant collaborations with research institutions and pharmaceutical companies enhance BIO's research capabilities and market reach, contributing to its overall earnings.

Biome Australia Ltd Financial Statement Overview

Summary

Solid revenue growth (16.14%) and a strong gross margin (61.12%) support the outlook, and the balance sheet appears stable with moderate leverage (debt-to-equity 0.66). Offsetting this, profitability is thin (net margin 1.17%) and operating cash flow is negative, indicating weak cash conversion despite improved free cash flow growth.

Income Statement

Biome Australia Ltd has shown a positive revenue growth rate of 16.14% in the latest year, indicating strong top-line growth. The gross profit margin is healthy at 61.12%, reflecting efficient cost management. However, the net profit margin is low at 1.17%, suggesting limited profitability after expenses. The EBIT and EBITDA margins are also low, indicating room for improvement in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio of 0.66 indicates a moderate level of leverage, which is manageable. The return on equity is positive at 4.59%, showing that the company is generating returns for its shareholders. The equity ratio is strong, suggesting a solid capital structure with a good proportion of equity financing.

Cash Flow

The free cash flow growth rate is significantly high at 314.74%, indicating improved cash generation. However, the operating cash flow is negative, and the operating cash flow to net income ratio is also negative, highlighting challenges in converting profits into cash. The free cash flow to net income ratio is slightly above 1, showing that free cash flow is covering net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.42M	18.42M	13.01M	7.24M	4.11M	2.32M
Gross Profit	11.26M	11.26M	7.91M	4.06M	2.38M	1.07M
EBITDA	143.57K	143.57K	-1.58M	-3.15M	-4.65M	-5.39M
Net Income	214.66K	214.66K	-1.67M	-3.08M	-4.54M	-5.38M
Balance Sheet
Total Assets	11.97M	11.97M	8.28M	7.56M	8.25M	11.09M
Cash, Cash Equivalents and Short-Term Investments	2.75M	2.75M	2.87M	2.26M	5.49M	634.61K
Total Debt	3.07M	3.07M	1.30M	1.15M	467.05K	81.00K
Total Liabilities	7.29M	7.29M	5.37M	3.97M	1.73M	920.00K
Stockholders Equity	4.68M	4.68M	2.90M	3.59M	6.53M	10.17M
Cash Flow
Free Cash Flow	-2.86M	-2.86M	-185.41K	-3.90M	-3.55M	-2.46M
Operating Cash Flow	-2.82M	-2.82M	-163.81K	-3.50M	-3.42M	-2.39M
Investing Cash Flow	-200.38K	-200.38K	-21.61K	-400.94K	-99.34K	-28.77K
Financing Cash Flow	2.90M	2.90M	793.17K	665.21K	8.40M	2.58M

Biome Australia Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Positive. The current price of 0.4 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.42, and below the 200-day MA of 0.47, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.16 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BIO.

Biome Australia Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BIO	57 Neutral	AU$100.17M	465.00	5.66%	―	41.57%	―
BGT	46 Neutral	AU$9.15M	-2.54	―	―	―	―
AVE	44 Neutral	AU$36.73M	-9.09	-143.71%	―	306.88%	―
ANR	41 Neutral	AU$4.39M	-1.46	-205.70%	―	―	1.03%
HXL	40 Underperform	AU$2.17M	-4.33	-28.49%	―	―	46.43%
1AD	37 Underperform	AU$11.48M	-1.61	-628.72%	―	―	31.87%

Biome Australia Ltd Corporate Events

Biome Australia Delivers Record Quarter With Strong Revenue Growth and Cash Generation

Biome Australia reported its strongest quarter on record for the three months to 31 December 2025, with sales revenue of $6.5 million, up 41% on the prior corresponding period, and rolling 12‑month revenue of about $22 million. The company delivered EBITDA of approximately $1.0 million for the quarter and $1.48 million for the first half of FY26, marking its eighth consecutive quarter of positive EBITDA, while maintaining gross margins above 61%. Cash receipts rose 43% to $6.2 million, and together with an R&D rebate, generated about $1.24 million in net operating cash inflow, enabling Biome to repay $722,000 of working capital facilities and lift its cash balance by $421,000 to $3.36 million, underscoring stronger cash generation and an improving balance sheet.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Posts Record Q2 and Half-Year Sales on Strong Probiotic Demand

Biome Australia reported record sales for the second quarter and first half of FY26, with Q2 revenue reaching $6.48 million, up 40.9% on the prior corresponding period and 9.1% sequentially, despite Q2 typically being seasonally softer due to fewer December trading days and a pharmacy sector focus on gifting. Half-year FY26 revenue rose 40.2% to $12.42 million, underpinned by strong demand for the company’s clinically proven probiotic products, reinforcing its growth trajectory and indicating strengthening market adoption in its core complementary medicines and live biotherapeutics segments.

The most recent analyst rating on (AU:BIO) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Appoints New CFO to Drive International Expansion

Biome Australia Limited has appointed Lauren Dwyer as the new Chief Financial Officer, effective February 2026. Dwyer brings extensive experience from various sectors, including SaaS and healthcare, and has a proven track record in international expansion and financial leadership. Her appointment is expected to support Biome’s international growth and strategic objectives, particularly Vision 27. The outgoing CFO, Douglas Loh, will retire after a comprehensive handover, maintaining an advisory role.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Director Increases Stake, Signaling Growth Confidence

Biome Australia Limited announced a change in the director’s interest, with Geoffrey Sam acquiring 2,000,000 fully paid ordinary shares under the company’s Loan Funded Share Plan, valued at approximately $803,640. This acquisition, approved at the Annual General Meeting, reflects strategic alignment and potential growth in shareholder value, indicating confidence in the company’s future prospects.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Facilitates Share Trading with New Issuance

Biome Australia Ltd has issued 2,000,000 fully paid ordinary shares under its Loan Funded Share Plan, a move approved at its recent Annual General Meeting. This issuance, compliant with the Corporations Act 2001, allows the shares to be traded without disclosure, potentially enhancing liquidity and investor engagement.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Director Increases Shareholding

Biome Australia Limited has announced a change in the director’s interest in securities, specifically involving Blair Vega Norfolk. The director acquired an additional 50,000 fully paid ordinary shares through an on-market purchase, increasing their total holdings to 327,317 shares. This change reflects a strategic move by the director, potentially signaling confidence in the company’s future performance and impacting stakeholder perceptions.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

Biome Australia Limited Announces AGM Results with Strong Shareholder Support

Biome Australia Limited announced the results of its Annual General Meeting, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of director Mr. Geoffrey Sam, ratification of prior issue of shares to advisors, approval of proposed issue of loan-funded shares to Geoffrey Sam, and approval of additional 10% placement capacity. These results reflect strong shareholder support and are likely to positively impact the company’s governance and strategic initiatives.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.